Tanya Zharov - Alvotech General Counsel
| ALVO Stock | USD 11.75 0.07 0.60% |
Executive
Tanya Zharov is General Counsel of Alvotech
| Age | 57 |
| Address | 9, Rue de Bitbourg, Luxembourg City, Luxembourg, 1273 |
| Phone | 354 422 4500 |
| Web | https://www.alvotech.com |
Alvotech Management Efficiency
The company has return on total asset (ROA) of (0.0761) % which means that it has lost $0.0761 on every $100 spent on assets. This is way below average. Alvotech's management efficiency ratios could be used to measure how well Alvotech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Return On Tangible Assets is likely to drop to -0.63. In addition to that, Return On Capital Employed is likely to drop to -0.54. At this time, Alvotech's Intangible Assets are very stable compared to the past year. As of the 1st of December 2024, Intangibles To Total Assets is likely to grow to 0.05, while Total Assets are likely to drop about 784 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mannam Venkatanarasimham | Dr Reddys Laboratories | N/A | |
| Max Reinhardt | Pacira BioSciences, | 53 | |
| Blair Jackson | Alkermes Plc | 51 | |
| Dejan Lamesic | Catalent | N/A | |
| Steve Laninga | Lifecore Biomedical | N/A | |
| Sam Schlessinger | Assertio Therapeutics | 42 | |
| Sandeep Poddar | Dr Reddys Laboratories | N/A | |
| Dan MBA | Amphastar P | N/A | |
| Sushrut Kulkarni | Dr Reddys Laboratories | 54 | |
| Bill Iskos | Assertio Therapeutics | N/A | |
| Sumera Hasham | Dr Reddys Laboratories | N/A | |
| Thomas Rowland | ANI Pharmaceuticals | 57 | |
| Declan OConnor | Alkermes Plc | N/A | |
| Deepak Sapra | Dr Reddys Laboratories | 45 | |
| Peter Norman | Alkermes Plc | N/A | |
| MP MBA | Amphastar P | N/A | |
| Susan Mesco | Pacira BioSciences, | N/A | |
| Paul Surdez | Catalent | N/A | |
| YUGANDHAR PUVVALA | Dr Reddys Laboratories | 48 | |
| Dennis McLoughlin | Pacira BioSciences, | 58 | |
| Karen Esq | Intracellular Th | 62 | |
Management Performance
| Return On Asset | -0.0761 |
Alvotech Leadership Team
Elected by the shareholders, the Alvotech's board of directors comprises two types of representatives: Alvotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alvotech. The board's role is to monitor Alvotech's management team and ensure that shareholders' interests are well served. Alvotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alvotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christina Siniscalchi, Interim Officer | ||
| Ming Li, Chief Officer | ||
| Sandra Casaca, Chief Officer | ||
| RoseMarie Ohlsson, Chief Officer | ||
| Anil Okay, Chief Officer | ||
| Giedrius Zunda, Chief Officer | ||
| Sean Gaskell, Chief Officer | ||
| Joel Morales, Chief Officer | ||
| Joseph McClellan, Chief Officer | ||
| Eva Gunnlaugsdottir, Vice Culture | ||
| Tanya Zharov, General Counsel | ||
| Faysal Kalmoua, COO Director | ||
| Mark Levick, Chief Officer | ||
| Sigridur Gudlaugsdottir, VP HR | ||
| Jenny Steingrimsdottir, Vice Culture | ||
| Robert Wessman, Founder Directors |
Alvotech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alvotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.0761 | ||||
| Profit Margin | (2.00) % | ||||
| Operating Margin | 0.46 % | ||||
| Current Valuation | 4.61 B | ||||
| Shares Outstanding | 301.94 M | ||||
| Shares Owned By Insiders | 64.01 % | ||||
| Shares Owned By Institutions | 6.03 % | ||||
| Number Of Shares Shorted | 116.79 K | ||||
| Price To Sales | 11.49 X | ||||
| Revenue | 91.43 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alvotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Alvotech Stock, please use our How to Invest in Alvotech guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alvotech. If investors know Alvotech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alvotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.70) | Earnings Share (1.85) | Revenue Per Share 1.283 | Quarterly Revenue Growth 43.997 | Return On Assets (0.08) |
The market value of Alvotech is measured differently than its book value, which is the value of Alvotech that is recorded on the company's balance sheet. Investors also form their own opinion of Alvotech's value that differs from its market value or its book value, called intrinsic value, which is Alvotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alvotech's market value can be influenced by many factors that don't directly affect Alvotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alvotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alvotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alvotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.